These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38802194)

  • 21. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
    Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
    Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness Analysis of Human Papillomavirus Vaccination in Adolescent Girls in Taiwan.
    Tang CH; Cheng WF; Jiang JH; You SL; Huang LW; Hsieh JY; Mukherjee P; Van Kriekinge G; Lee C
    Asian Pac J Cancer Prev; 2019 May; 20(5):1377-1387. PubMed ID: 31127896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human papillomavirus genotype distribution among women with and without cervical cancer: Implication for vaccination and screening in Ghana.
    Nartey Y; Amo-Antwi K; Hill PC; Dassah ET; Asmah RH; Nyarko KM; Agambire R; Konney TO; Yarney J; Damale N; Cox B
    PLoS One; 2023; 18(1):e0280437. PubMed ID: 36656844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S;
    Vaccine; 2013 Dec; 31 Suppl 5():F1-31. PubMed ID: 24331745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Knowledge of Cervical Cancer, Human Papilloma Virus (HPV) and HPV Vaccination Among Women in Northeast China.
    Ning YE; Liu Y; Xu XY; Zhang XY; Wang N; Zheng LQ
    J Cancer Educ; 2020 Dec; 35(6):1197-1205. PubMed ID: 31338812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
    Du J; Ährlund-Richter A; Näsman A; Dalianis T
    Arch Gynecol Obstet; 2021 Feb; 303(2):329-335. PubMed ID: 33247317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany].
    Schneider A; Schwarz TF; Hammerschmidt T; Siebert U
    Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
    Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
    Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
    Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
    Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.
    Gertig DM; Brotherton JM; Budd AC; Drennan K; Chappell G; Saville AM
    BMC Med; 2013 Oct; 11():227. PubMed ID: 24148310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S;
    Vaccine; 2013 Nov; 31 Suppl 8(0 8):I1-31. PubMed ID: 24229716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of HPV vaccination in women reaching screening age in Italy.
    Carozzi FM; Ocello C; Burroni E; Faust H; Zappa M; Paci E; Iossa A; Bonanni P; Confortini M; Sani C
    J Clin Virol; 2016 Nov; 84():74-81. PubMed ID: 27728850
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
    Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
    Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa.
    Snyman LC; Dreyer G; Visser C; Botha MH; van der Merwe FH
    S Afr Med J; 2015 Mar; 105(3):191-4. PubMed ID: 26294825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
    Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
    Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.